Advances of PSMA-targeted fluorescence probes in prostate cancer imaging

doi:10.3877/cma.j.issn.1674-3253.2025.05.001

Abstract

Abstract:

The challenge in prostate cancer surgery lies in achieving a balance between complete tumor resection and preservation of surrounding functional structures within the confined pelvic space. Currently, there is a lack of intraoperative real-time imaging techniques with both high sensitivity and high specificity to accurately locate the tumor and delineate its extension. The development and clinical translation of prostate-specific membrane antigen (PSMA)-targeted fluorescence probes provide a novel strategy. This article systematically reviews the advances in PSMA-targeted fluorescence probes for preclinical research and clinical applications in prostate cancer, as well as PSMA-targeted radionuclide/fluorescence dual-modal probes.

Key words: Prostate cancer, Fluorescence probe, Prostate-specific membrane antigen, Image-guided surgery

Silu Chen, Xing Yang, Xuesong Li, Cheng Shen. Advances of PSMA-targeted fluorescence probes in prostate cancer imaging[J]. Chinese Journal of Endourology(Electronic Edition), 2025, 19(05): 547-551.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhqjmnmwkzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3253.2025.05.001

https://zhqjmnmwkzz.cma-cmc.com.cn/EN/Y2025/V19/I05/547

References 29

[1]	Mottet N, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. part 1: screening, diagnosis, and local treatment with curative intent[J]. Eur Urol, 2021, 79(2): 243-262. DOI: 10.1016/j.eururo.2020.09.042.
[2]	Chow KM, So WZ, Lee HJ, et al. Head-to-head comparison of the diagnostic accuracy of prostate-specific membrane antigen positron emission tomography and conventional imaging modalities for initial staging of intermediate- to high-risk prostate cancer: a systematic review and meta-analysis[J]. Eur Urol, 2023, 84(1): 36-48. DOI: 10.1016/j.eururo.2023.03.001.
[3]	Martini A, Gandaglia G, Fossati N, et al. Defining clinically meaningful positive surgical margins in patients undergoing radical prostatectomy for localised prostate cancer[J]. Eur Urol Oncol, 2021, 4(1): 42-48. DOI: 10.1016/j.euo.2019.03.006.
[4]	Moris L, Gandaglia G, Vilaseca A, et al. Evaluation of oncological outcomes and data quality in studies assessing nerve-sparing versus non-nerve-sparing radical prostatectomy in nonmetastatic prostate cancer: a systematic review[J]. Eur Urol Focus, 2022, 8(3): 690-700. DOI: 10.1016/j.euf.2021.05.009.
[5]	de Jong JM, Hoogendam JP, Braat AT, et al. The feasibility of folate receptor alpha- and HER2-targeted intraoperative fluorescence-guided cytoreductive surgery in women with epithelial ovarian cancer: a systematic review[J]. Gynecol Oncol, 2021, 162(2): 517-525. DOI: 10.1016/j.ygyno.2021.05.017.
[6]	Zhou Q, van den Berg NS, Rosenthal EL, et al. EGFR-targeted intraoperative fluorescence imaging detects high-grade glioma with panitumumab-IRDye800 in a phase 1 clinical trial[J]. Theranostics, 2021, 11(15): 7130-7143. DOI: 10.7150/thno.60582.
[7]	张继燊, 谢玉洁, 杨婷, 等. 前列腺特异性膜抗原PET/CT对减少前列腺癌过度穿刺活检的应用价值[J]. 中山大学学报(医学科学版), 2025, 46(2): 311-317. DOI: 10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).2025.0215.
[8]	Fizazi K, Herrmann K, Krause BJ, et al. Health-related quality of life and pain outcomes with [¹⁷⁷Lu] Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial[J]. Lancet Oncol, 2023, 24(6): 597-610. DOI: 10.1016/S1470-2045(23)00158-4.
[9]	Uspenskaia AA, Krasnikov PA, Majouga AG, et al. Fluorescent conjugates based on prostate-specific membrane antigen ligands as an effective visualization tool for prostate cancer[J]. Biochemistry (Mosc), 2023, 88(7): 953-967. DOI: 10.1134/S0006297923070088.
[10]	吴波. 前列腺癌荧光导航手术的临床研究与前列腺癌特异性荧光探针的临床前研究[D]. 山西: 山西医科大学, 2021.
[11]	Hensbergen AW, van Willigen DM, van Beurden F, et al. Image-guided surgery: are we getting the most out of small-molecule prostate-specific-membrane-antigen-targeted tracers?[J]. Bioconjug Chem, 2020, 31(2): 375-395. DOI: 10.1021/acs.bioconjchem.9b00758.
[12]	Humblet V, Lapidus R, Williams LR, et al. High-affinity near-infrared fluorescent small-molecule contrast agents for in vivo imaging of prostate-specific membrane antigen[J]. Mol Imaging, 2005, 4(4): 448-462. DOI: 10.2310/7290.2005.05163.
[13]	Chen Y, Dhara S, Banerjee SR, et al. A low molecular weight PSMA-based fluorescent imaging agent for cancer[J]. Biochem Biophys Res Commun, 2009, 390(3): 624-629. DOI: 10.1016/j.bbrc.2009.10.017.
[14]	Neuman BP, Eifler JB, Castanares M, et al. Real-time, near-infrared fluorescence imaging with an optimized dye/light source/camera combination for surgical guidance of prostate cancer[J]. Clin Cancer Res, 2015, 21(4): 771-780. DOI: 10.1158/1078-0432.CCR-14-0891.
[15]	Wang X, Huang SS, Heston WDW, et al. Development of targeted near-infrared imaging agents for prostate cancer[J]. Mol Cancer Ther, 2014, 13(11): 2595-2606. DOI: 10.1158/1535-7163.MCT-14-0422.
[16]	Zhang L, Shi X, Li Y, et al. Visualizing tumors in real time: a highly sensitive PSMA probe for NIR-II imaging and intraoperative tumor resection[J]. J Med Chem, 2021, 64(11): 7735-7745. DOI: 10.1021/acs.jmedchem.1c00444.
[17]	Kularatne SA, Thomas M, Myers CH, et al. Evaluation of novel prostate-specific membrane antigen-targeted near-infrared imaging agent for fluorescence-guided surgery of prostate cancer[J]. Clin Cancer Res, 2019, 25(1): 177-187. DOI: 10.1158/1078-0432.CCR-18-0803.
[18]	Stibbe JA, de Barros HA, Linders DGJ, et al. First-in-patient study of OTL78 for intraoperative fluorescence imaging of prostate-specific membrane antigen-positive prostate cancer: a single-arm, phase 2a, feasibility trial[J]. Lancet Oncol, 2023, 24(5): 457-467. DOI: 10.1016/S1470-2045(23)00102-X.
[19]	Nguyen HG, van den Berg NS, Antaris AL, et al. First-in-human evaluation of a prostate-specific membrane antigen-targeted near-infrared fluorescent small molecule for fluorescence-based identification of prostate cancer in patients with high-risk prostate cancer undergoing robotic-assisted prostatectomy[J]. Eur Urol Oncol, 2024, 7(1): 63-72. DOI: 10.1016/j.euo.2023.07.004.
[20]	Eder AC, Omrane MA, Stadlbauer S, et al. The PSMA-11-derived hybrid molecule PSMA-914 specifically identifies prostate cancer by preoperative PET/CT and intraoperative fluorescence imaging[J]. Eur J Nucl Med Mol Imaging, 2021, 48(6): 2057-2058. DOI: 10.1007/s00259-020-05184-0.
[21]	Lütje S, Rijpkema M, Franssen GM, et al. Dual-modality image-guided surgery of prostate cancer with a radiolabeled fluorescent anti-PSMA monoclonal antibody[J]. J Nucl Med, 2014, 55(6): 995-1001. DOI: 10.2967/jnumed.114.138180.
[22]	Baranski AC, Schäfer M, Bauder-Wüst U, et al. PSMA-11-derived dual-labeled PSMA inhibitors for preoperative PET imaging and precise fluorescence-guided surgery of prostate cancer[J]. J Nucl Med, 2018, 59(4): 639-645. DOI: 10.2967/jnumed.117.201293.
[23]	Eder AC, Schäfer M, Schmidt J, et al. Rational linker design to accelerate excretion and reduce background uptake of peptidomimetic PSMA-targeting hybrid molecules[J]. J Nucl Med, 2021, 62(10): 1461-1467. DOI: 10.2967/jnumed.120.248443.
[24]	Kommidi H, Guo H, Nurili F, et al. ¹⁸F-positron emitting/trimethine cyanine-fluorescent contrast for image-guided prostate cancer management[J]. J Med Chem, 2018, 61(9): 4256-4262. DOI: 10.1021/acs.jmedchem.8b00240.
[25]	Aras O, Demirdag C, Kommidi H, et al. Small molecule, multimodal, [¹⁸F]-PET and fluorescence imaging agent targeting prostate-specific membrane antigen: first-in-human study[J]. Clin Genitourin Cancer, 2021, 19(5): 405-416. DOI: 10.1016/j.clgc.2021.03.011.
[26]	Fu H, Lou K, He H, et al. A novel PSMA targeted dual-function near-infrared fluorescence and PET probe for the image-guided surgery and detection of prostate cancer[J]. Eur J Nucl Med Mol Imaging, 2024, 51(10): 2998-3008. DOI: 10.1007/s00259-023-06492-x.
[27]	Duan X, Liu F, Kwon H, et al. (S)-3-(Carboxyformamido)-2-(3-(carboxymethyl)ureido)propanoic Acid as a Novel PSMA Targeting Scaffold for Prostate Cancer Imaging[J]. J Med Chem, 2020, 63(7): 3563-3576. DOI: 10.1021/acs.jmedchem.9b02031.
[28]	Duan X, Cao Z, Zhu H, et al. ⁶⁸Ga-labeled ODAP-Urea-based PSMA agents in prostate cancer: first-in-human imaging of an optimized agent[J]. Eur J Nucl Med Mol Imaging, 2022, 49(3): 1030-1040. DOI: 10.1007/s00259-021-05486-x.
[29]	Li Y, Duan X, Xu H, et al. Optimization of ODAP-Urea-based dual-modality PSMA targeting probes for sequential PET-CT and optical imaging[J]. Bioorg Med Chem, 2022, 66: 116810. DOI: 10.1016/j.bmc.2022.116810.

Please choose a citation manager

Content to export